Search | Clinical Trials Finder

Conditions: Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild, Major Depression Moderate, Major Depression Severe
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Extended-Release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more

Conditions: Depressive Symptoms, Quality of Life
Interventions: Trust-building Self-management Together, Depression Management; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 14 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anxiety Disorder, Chronic Myeloproliferative Disorders, Depression, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Pain
Interventions: pain therapy, psychosocial assessment and care; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Moderate Depression
Interventions: CBT-txt; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 25 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pain, Respiratory Depression
Interventions: Hydromorphone, Usual care group; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 60 Years to 90 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
Interventions: nebulized ketamine, nebulized midazolam; Drug
Lead sponsor: Theresa Jacob, PhD, MPH; Other
Eligibility: 18 Years to 88 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Major Depressive Disorder
Interventions: Placebo, Escitalopram, JNJ-18038683; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 26
States / cities: Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more

Conditions: Bipolar Depression, Suicidal Ideation
Interventions: NRX-101, Lurasidone HCl, Placebo; Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Anxiety, Agitated Depression
Interventions: Music Listening, Listening to Audiobooks; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 65 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression
Interventions: Magnesium sulfate; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Major Depressive Disorder
Interventions: Azetukalner, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Dothan, Alabama • Huntsville, Alabama • Bentonville, Arkansas + 30 more

Conditions: Parkinson's Disease, Depression
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 35 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Mild to Moderate Depression
Interventions: TESA-HB Transcranial Electronic Stimulation Device; Device
Lead sponsor: Annecto LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bensalem, Pennsylvania

Conditions: Postpartum Depression
Interventions: Placebo, SAGE-547 90 μg/kg/h; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 32
States / cities: Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more

Conditions: Major Depressive Disorder, Traumatic Brain Injury
Interventions: Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions: Placebo, Escitalopram; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depression and/or Anxiety in the Mild-to-moderate Range
Interventions: Clinician-administered Need-focused Single Session Intervention; Behavioral
Lead sponsor: Bar-Ilan University, Israel; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Treatment Resistant Depression
Interventions: Ketamine Infusion plus RO DBT; Combination Product
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depression
Interventions: Psychoeducation, Behavioral Activation; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depression Moderate, Major Depression Severe, Major Depression
Interventions: LSD, Risperidone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depression, Mental Health
Interventions: Provigil; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 4
States / cities: Stanford, California • Atlanta, Georgia • New York, New York + 1 more

Conditions: Postpartum Depression
Interventions: WB001, ED001; Device
Lead sponsor: Woebot Health; Industry
Eligibility: 22 Years to 45 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Lafayette, California • Santa Ana, California • DeLand, Florida + 5 more

Search by objective public record fields.

MRS and Medication Response: A Pilot Study

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

Effects of Antidepressants on Sexual Functioning

Testing TRUST Depression Management Intervention

Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation

Treating Depression With Text Messaging

Study of Respiratory Depression When Using a Hydromorphone Pain Protocol

Nebulized Ketamine for the Treatment of Major Depressive Disorder

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

NRX101 Glx Biomarker Validation Study

The Effects of Music Listening on Anxiety and Agitation in People With Mild and Moderate Cognitive Impairment

Magnesium Sulfate Versus 5% Dextrose With Treatment Resistant Depression

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Cognitive Behavioral Therapy for Depression in Parkinson's Disease

Pilot Study Using Transcranial Electrostimulation (TESA-HB) Therapy for the Treatment of Depressive Symptoms

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

Personalized Need-focused Single Session Intervention

KET-RO Plus RO DBT for Treatment Resistant Depression

Neuroscience of Psychotherapy for Depression

Shortened LSD Intervention for Major Depressive Disorder

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]